Skip to main content
Premium Trial:

Request an Annual Quote

HUPO President Says 2002 Will Be the Year of the Proteome

NEW YORK, Jan. 25 - Human Proteome Organization President Sam Hanash said he expects 2002 to be critical both for proteomics companies and for HUPO as the two try to prove they can live up to their potential.

"For groups and companies [that] declared one or two years ago that their goals are doing something big in proteomics, then I think by 2002 they should have had enough of a lead time to tell the world what it is that they have done," Hanash said in a recent interview.

He cited Myriad Genetics and Celera Genomics as two examples of companies that have promised much but so far delivered little. Celera, for example, has raised close to a billion dollars toward its proteomics efforts, Hanash added, and by the end of 2002 the company will have spent two years studying the proteome.

"Knowing that it took less than that to do the whole genome I would like to know how much they've been able to do with respect to the proteome," he said.

But Hanash indicated that the private sector's ability to fulfill its promises is not necessarily divorced from HUPO's fortunes. On the other hand, Hanash said the potential for the major players to fall short of their goals presents opportunities for his organization because a poor performance by a corporation could make collaborations with academics more attractive.

"The contrasting view is that no one platform will tackle it all, and this creates opportunities for community efforts," Hanash said.

In its first year, however, HUPO was unable to rally its members around a common scientific cause, and Hanash admitted that the organization will face pressure to prove that it can take on a leadership role.

"There has yet to be a formulation of what a major public initiative in proteomics would look like, be it a proteome project, or a multitude of proteome projects," he said. "So I think 2002 is going to be crucial with respect to sketching out what a major public proteomics initiative would look like."

Hanash said his other goals for HUPO during the year include holding its first annual congress and sponsoring training workshops. "HUPO would be expected to be definitely running as an established organization in 2002," he said.

HUPO's role in training scientists and graduate students in proteomics is especially important, Hanash said, because of the number of academic scientists who have migrated to industry over the last year.

"Maybe that will reach equilibrium in a year or so," he said, "but HUPO is very aware [of the need for training], and that's part of our mission."


This article originally appeared in ProteoMonitor.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.